骨疏康胶囊治疗糖皮质激素性骨质疏松症的临床研究

发布时间：2018-03-18 12:01

  本文选题：骨疏康胶囊　切入点：糖皮质激素性骨质疏松症　出处：《中国骨质疏松杂志》2017年06期 　论文类型：期刊论文

【摘要】：目的观察骨疏康胶囊治疗糖皮质激素性骨质疏松症的疗效。方法选取宁夏医科大学总医院门诊及住院确诊的风湿性疾病并糖皮质激素性骨质疏松症患者80例,随机分为试验组和对照组,每组各40例。试验组患者口服骨疏康胶囊4粒BID,阿法骨化醇软胶囊0.5μg QD,碳酸钙D3片1片BID,对照组患者口服阿法骨化醇软胶囊0.5μg QD,碳酸钙D3片1片BID,两组均连续用药12个月,观察其骨密度及骨代谢指标的变化。结果试验组腰椎(L1~4)、股骨颈、大转子、全髋的骨密度均较对照组升高,与治疗前相比明显升高,差异均具有统计学意义(P0.05)。骨代谢指标中,试验组血清钙治疗前后无明显变化(P0.05),骨钙素、碱性磷酸酶降低,25-羟维生素D、Ⅰ型前胶原N端前肽升高,差异均有统计学意义(P0.05)。与对照组比较,血清钙与骨钙素无明显变化(P0.05),碱性磷酸酶降低,25-羟维生素D、Ⅰ型前胶原N端前肽升高,差异均具有统计学意义(P0.05)。结论骨疏康胶囊可改善糖皮质激素性骨质疏松症患者的骨密度和骨代谢,具有临床使用价值。
[Abstract]:Objective to observe the curative effect of Gushukang capsule on glucocorticoid-induced osteoporosis. Methods 80 patients with rheumatic diseases and glucocorticoid osteoporosis were selected from outpatient and inpatient department of Ningxia Medical University General Hospital. They were randomly divided into two groups: experimental group and control group. There were 40 cases in each group. The patients in the test group were treated with BID4 tablets of Guxukang capsule, 0.5 渭 g QDof Alfacalcitrate soft capsule, 1 tablet of calcium carbonate D3, and 1 tablet of BID1 of Alfacalciferol soft capsule and calcium carbonate D3 tablet in the control group. The two groups were treated continuously for 12 months, and the patients in the control group were treated by oral administration of 0.5 渭 g QD and 1 tablet of calcium carbonate in the control group. Results the bone mineral density (BMD) of the lumbar spine, femoral neck, trochanter and total hip in the experimental group was significantly higher than that in the control group, and the difference was statistically significant (P 0.05). There were no significant changes in serum calcium, osteocalcin and alkaline phosphatase in the experimental group before and after treatment. The levels of 25-hydroxyvitamin D and procollagen 鈪，

本文编号：1629484